This is the authors' abstract. We don't add key points for this paper.
Introduction Recent studies suggest that type 2 diabetes mellitus (T2DM) is characterized by a systemic, low-grade chronic inflammatory state. Although cow milk protein (CMP) has been shown to alleviate this inflammation, its underlying mechanisms remain unclear. Methods Therefore, we investigated how CMP mitigates systemic chronic inflammation in T2DM using both in vitro digestion and mouse models. Results The in vitro digestion model demonstrated that CMP, with its low degree of hydrolysis, exhibits significant anti-α-amylase and antioxidant activities. In the in vivo study, CMP markedly reduced fasting blood glucose (FBG) and reversed diabetes-related body weight loss. CMP intervention significantly decreased oxidative stress markers, including malondialdehyde (MDA) and reactive oxygen species (ROS), while enhancing the activity of the antioxidant enzyme glutathione peroxidase (GSH-Px). Moreover, CMP suppressed macrophage polarization toward the M1 phenotype and reduced the levels of pro-inflammatory cytokines. Finally, CMP administration ameliorated lipid infiltration in the liver and intestine, mitigated pancreatic islet atrophy, and concurrently alleviated renal pathologies such as glomerular hypertrophy, glycation, and fibrosis. Discussion In conclusion, CMP ameliorates systemic chronic inflammation in T2DM by disrupting the ROS–M1 macrophage vicious cycle.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: